Previous 10 | Next 10 |
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical need conditions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on ...
HANOVER, MD, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a co...
Processa Pharmaceuticals (NASDAQ: PCSA) , a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients who have an unmet medical need conditions, is reporting positive results from its ongoing Next-Generation Capecitabine (“NGC&...
Next Generation Capecitabine (NGC) D osage R egimens H ave B een I dentified I n T he O ngoing Phase 1B T rial W ith P otentially B etter S afety A nd E fficacy P ...
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical stage biopharmaceutical company focused on developing products to improve survival and/or quality of life for patients who have an unmet medical need condition for which there are few or no therapeutic options, has released update informa...
PCS12852 for Gastroparesis concluded enrollment a month ahead of schedule. Statistics on gastric emptying, safety and GEBT data will be available by the end of October and full topline data is expected before year end. New site added for PCS6422 to accelerate enrollment, important dat...
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition, will be part of the 22nd annual H.C. Wainwright Global Investment Conference. Proces...
HANOVER, MD, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition today announced that Dr. Dr. Dav...
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, has announced new board appointments. The company named Kho...
Board A ppointments Designed to Position Company for Anticipated Milestones While Ensuring Adherence to the Highest Governance Standards HANOVER, MD, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage bioph...
News, Short Squeeze, Breakout and More Instantly...
Processa Pharmaceuticals Inc. Company Name:
PCSA Stock Symbol:
OTCMKTS Market:
Processa Pharmaceuticals Inc. Website:
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, has named a new chief financial officer. According to the announcement, Russell L. Skibsted has accepted the new...
HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announces the appointment of Ru...
Processa (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive efficacy results from the preliminary evaluation of its recently completed Phase 1b clinical trial. The...